UPDATED NCCN Guidelines for non-small cell lung cancer (NSCLC) detail expanded systemic therapy options that strengthen outcomes for patients with resectable and unresectable disease.
Advances in Resectable NSCLC Management
The updated guidelines reflect major shifts driven by Phase III data supporting immunotherapy use around the time of surgery. Surgical resection remains the foundation for early-stage disease; however, recurrence risks persist even after complete removal. Historically, neoadjuvant or adjuvant platinum chemotherapy provided modest benefit, prompting evaluation of immune checkpoint inhibitors as alternative strategies.
Three perioperative regimens now carry category 1 recommendations following landmark trials. Pembrolizumab, durvalumab, and nivolumab combinations with platinum-based chemotherapy improved event-free survival and increased pathologic complete response rates, with benefits observed regardless of PD-L1 status. These regimens involve coordinated neoadjuvant and adjuvant therapy and are recommended for tumors measuring at least 4 cm or with nodal involvement.
Neoadjuvant nivolumab plus chemotherapy remains an option when adjuvant immunotherapy is not planned. Separate adjuvant use of atezolizumab or pembrolizumab continues for select patients with completely resected disease following chemotherapy. Clinicians must consider contraindications, including autoimmune disease and specific oncogenic drivers that reduce immunotherapy benefit.
Targeted Therapy in Resected NSCLC
Targeted therapy options have expanded beyond osimertinib. Adjuvant alectinib demonstrated significant disease-free survival benefits for patients with ALK-positive resected NSCLC and is now a category 1 recommendation. Osimertinib remains recommended for eligible EGFR-mutated disease. Additional data from ongoing studies signal further growth in targeted options.
Treatment Updates for Unresectable Stage II/III NSCLC
For patients receiving definitive concurrent chemoradiation, consolidation therapy options now include both durvalumab and osimertinib, depending on molecular features. Durvalumab continues to show durable survival benefit, while osimertinib demonstrated substantial progression-free survival for EGFR-mutated tumors. Both agents are Category 1 recommendations for Stage III disease.
Evolving Role of Molecular and PD-L1 Testing
Molecular testing is emphasized as essential for patients with nonmetastatic NSCLC, particularly for identifying EGFR and ALK alterations that influence neoadjuvant, adjuvant, and consolidation strategies. At minimum, testing for EGFR, ALK, and PD-L1 should be performed for all resectable Stage IB–IIIB tumors. Turnaround time remains a key consideration, with rapid assays preferred to avoid delaying potentially curative therapy.
Summary
The updated NCCN NSCLC guidelines incorporate substantial new evidence supporting perioperative immunotherapy, expanded targeted therapy options, and precision-guided consolidation strategies. These recommendations highlight the growing role of molecular profiling in directing therapy decisions across early-stage disease and aim to improve long-term survival through tailored and timely treatment.
Reference: National Comprehensive Cancer Network (NCCN). NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025. 2025. Available at: https://jnccn.org/view/journals/jnccn/23/9/article-p354.xml. Last accessed: November 18, 2025.
